About renovorx inc - RNXT
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in 2009 and is headquartered in Mountain View, CA.
RNXT At a Glance
RenovoRx, Inc.
2570 West El Camino Real
Mountain View, California 94040
| Phone | 1-650-284-4433 | Revenue | 1.12M | |
| Industry | Pharmaceuticals: Major | Net Income | -11,168,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 2,511.628% | |
| Fiscal Year-end | 12 / 2026 | Employees | 17 | |
| View SEC Filings |
RNXT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 26.432 |
| Price to Book Ratio | 5.673 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.829 |
| Enterprise Value to Sales | 20.366 |
| Total Debt to Enterprise Value | 0.009 |
RNXT Efficiency
| Revenue/Employee | 66,058.824 |
| Income Per Employee | -656,941.176 |
| Receivables Turnover | 8.079 |
| Total Asset Turnover | 0.137 |
RNXT Liquidity
| Current Ratio | 4.023 |
| Quick Ratio | 3.927 |
| Cash Ratio | 3.58 |
RNXT Profitability
| Gross Margin | 70.882 |
| Operating Margin | -1,113.98 |
| Pretax Margin | -994.479 |
| Net Margin | -994.479 |
| Return on Assets | -136.687 |
| Return on Equity | -225.616 |
| Return on Total Capital | -198.225 |
| Return on Invested Capital | -218.573 |
RNXT Capital Structure
| Total Debt to Total Equity | 3.91 |
| Total Debt to Total Capital | 3.763 |
| Total Debt to Total Assets | 2.603 |
| Long-Term Debt to Equity | 1.973 |
| Long-Term Debt to Total Capital | 1.899 |